A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.

Inclusion Criteria: * Patients 60-85 years old * Current or former smokers * BMI 25-35 * No cancer requiring active therapy within the last 2 years * No autoimmune disease requiring disease modifying agents * No patients with EGFR \160; diastolic \>100) * Patients with an inherited primary immunodeficiency * Patients may not have a history of, or current evidence of, clinically significant chronic liver disease * Patients may not be receiving any chronic immunosuppressive therapy. * Patients may not be receiving medications that could increase rapamycin blood concentrations, such as strong inhibitors and inducers of CYP3A4 and/or P-gp (ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin; rifampin or rifabutin), bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, protease inhibitors, metoclopramide, nicardipine, troleandomycin, verapamil. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort. * Patients may not be receiving medications that could decrease rapamycin blood concentrations, such as: carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort. * Patients may not be receiving medications known to cause angioedema with concomitant use of rapamycin, such as angiotensin-converting enzyme (ACE) inhibitors. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort.